Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329766 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
A Phase 2 study of Gastrointestinal Tract Malignancies, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT05329766: Active Phase 2 study of Gastrointestinal Tract Malignancies, sponsored by Arcus Biosciences.
NCT05329766 is a Phase 2 study of Gastrointestinal Tract Malignancies that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 332 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05329766, a Phase 2 study of Gastrointestinal Tract Malignancies, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Domvanalimab
Study Locations (20)
Other
- UHN - Princess Margaret Cancer Centre - Toronto
- Clínica San Carlos de Apoquindo - Las Condes
- Bradford Hill Centro de Investigaciones Clinicas - Recoleta
- Centro de Estudios Clínicos SAGA - Santiago
Florida
- Florida Cancer Specialist - South - Fort Myers
- Mayo Clinic - Jacksonville - Jacksonville
- Florida Cancer Specialist - North - St. Petersburg
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Santa Monica
New York
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University - New York
Tennessee
- SCRI Tennessee Oncology - Nashville - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Arizona
- Mayo Clinic - Arizona - Phoenix
Connecticut
- Yale Cancer Center - Derby
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT05329766 still lists
NCT05329766 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Gastrointestinal Tract Malignancies appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT05329766 names 20 study sites across 12 states, led by Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05329766 about?
NCT05329766 is a clinical study titled "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies". The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin...
What is the current status of trial NCT05329766?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2022-06-10. Estimated completion is 2027-06.
What conditions does trial NCT05329766 study?
This clinical trial studies the following conditions: Gastrointestinal Tract Malignancies.
What interventions are being tested in trial NCT05329766?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT05329766?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329766 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05329766's enrollment target sits among peer trials
332 144th of 2000 higher than 1,856 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI